Suppr超能文献

帕金森病相关痴呆。

Dementia in Parkinson's disease.

机构信息

Department of Neurology, CB 7025, The University of North Carolina at Chapel Hill, 3129 Physician Office Building, Chapel Hill, NC, 27599, USA,

出版信息

Curr Treat Options Neurol. 2011 Jun;13(3):242-54. doi: 10.1007/s11940-011-0121-1.

Abstract

Dementia in Parkinson's disease encompasses a spectrum relating to motor, psychiatric, and cognitive symptoms that are classified as either Dementia with Lewy Bodies (DLB) (initial cognitive symptoms) or Parkinson's Disease Dementia (PDD) (initial motor signs preceding cognitive symptoms by at least a year). Anticholinergic and antipsychotic drugs have a high risk of adverse cognitive and/or motor effects, so their use should be minimized or avoided. Neuroleptic sensitivity is a severe psychomotor adverse reaction that is particularly associated with potent dopamine-blocking agents such as haloperidol. It occurs in up to 50% of individuals with PDD or DLB. Mild psychotic symptoms should first be addressed by reducing anticholinergic and/or dopaminergic agents, if possible. Patients with psychotic symptoms that threaten the safety of the patient or caregiver may benefit from treatment with quetiapine or, in refractory cases, clozapine. Cholinesterase inhibitors as a drug class have been shown to have beneficial effects on cognition in DLB and PDD, and may help to alleviate some psychiatric symptoms, such as apathy, anxiety, hallucinations, and delusions. Memantine may help to moderate cognitive symptoms in DLB and PDD, although current data suggest a more variable response, particularly in PDD. Parkinsonian motor signs that are accompanied by clinically significant cognitive impairment should be treated with carbidopa/levodopa only, as dopamine agonists and other antiparkinsonian medications generally carry a higher risk of provoking or exacerbating psychotic symptoms. Excessive daytime sleepiness and REM sleep behavior disorder are common associated features of PDD and DLB. Minimizing sedating medications during the day and promoting nocturnal sleep may help the daytime sleepiness; melatonin, clonazepam, gabapentin, and possibly memantine may be useful in treating REM sleep behavior disorder. Orthostatic hypotension can be managed with various nonpharmacologic interventions, and if needed, fludrocortisone and pyridostigmine. Midodrine should be used cautiously, if at all.

摘要

帕金森病相关的痴呆涵盖了一系列与运动、精神和认知症状相关的疾病,这些症状可分为路易体痴呆(Lewy body dementia,DLB)(以认知症状为首发表现)或帕金森病痴呆(Parkinson's disease dementia,PDD)(以运动症状为首发表现,且认知症状比运动症状至少早 1 年出现)。抗胆碱能药物和抗精神病药物有发生认知和/或运动不良事件的高风险,因此应尽量减少或避免使用这些药物。神经阻滞剂敏感性是一种严重的精神运动不良反应,与强效多巴胺阻断剂(如氟哌啶醇)尤其相关。它可发生于高达 50%的 PDD 或 DLB 患者中。如果可能,首先应通过减少使用抗胆碱能药物和/或多巴胺能药物来处理轻度精神症状。对于有威胁到患者或照护者安全的精神病性症状的患者,可能需要使用喹硫平治疗,或者在难治性病例中使用氯氮平治疗。胆碱酯酶抑制剂作为一类药物,已被证明对 DLB 和 PDD 的认知功能有有益作用,并且可能有助于缓解一些精神症状,如淡漠、焦虑、幻觉和妄想。美金刚可能有助于改善 DLB 和 PDD 的认知症状,但目前的数据表明其反应更具变异性,特别是在 PDD 中。伴有明显认知障碍的帕金森运动症状应仅使用卡比多巴/左旋多巴治疗,因为多巴胺激动剂和其他抗帕金森药物通常会增加引发或加重精神病性症状的风险。日间过度嗜睡和 REM 睡眠行为障碍是 PDD 和 DLB 的常见相关特征。白天减少镇静药物和促进夜间睡眠可能有助于改善日间嗜睡;褪黑素、氯硝西泮、加巴喷丁和可能的美金刚可能对治疗 REM 睡眠行为障碍有用。体位性低血压可通过各种非药物干预措施进行管理,如果需要,还可使用氟氢可的松和吡啶斯的明。米多君应谨慎使用,如果使用的话。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验